205 related articles for article (PubMed ID: 37043179)
1. The Prognostic Nutritional Index before durvalumab after chemoradiation predict the overall survival in patients with stage III non-small cell lung cancer.
Matsuura S; Serizawa S; Yamashita R; Morikawa K; Ito Y; Hiramatsu T; Mochizuki E; Tanaka K; Akiyama N; Tsukui M; Koshimizu N; Kosugi T
Ann Med; 2023 Dec; 55(1):2196089. PubMed ID: 37043179
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.
Wang J; Liu Y; Mi X; Shao M; Liu L
Ann Palliat Med; 2020 May; 9(3):967-978. PubMed ID: 32389020
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
[TBL] [Abstract][Full Text] [Related]
4. Controlling Nutritional Status (CONUT) score is a prognostic marker in III-IV NSCLC patients receiving first-line chemotherapy.
Zhang Y; Kong FF; Zhu ZQ; Shan HX
BMC Cancer; 2023 Mar; 23(1):225. PubMed ID: 36894927
[TBL] [Abstract][Full Text] [Related]
5. The Geriatric Nutritional Risk Index and Prognostic Nutritional Index Predict the Overall Survival of Advanced Non-Small Cell Lung Cancer Patients.
Matsuura S; Morikawa K; Ito Y; Kubota T; Ichijo K; Mochizuki E; Akiyama N; Uehara M; Harada M; Tsukui M; Koshimizu N
Nutr Cancer; 2022; 74(5):1606-1613. PubMed ID: 34431441
[TBL] [Abstract][Full Text] [Related]
6. Chemoradiation followed by adjuvant durvalumab in stage III non-small cell lung cancer: Real-world comparison of treatment outcomes to historical controls treated with chemoradiation alone.
Saad A; Goldstein J; Appel S; Daher S; Urban D; Onn A; Gantz-Sorotsky H; Lobachov A; Gottfried T; Spieler B; Bar J
Thorac Cancer; 2022 Jun; 13(12):1763-1771. PubMed ID: 35538909
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors.
Guberina M; Guberina N; Pöttgen C; Gauler T; Richlitzki C; Metzenmacher M; Wiesweg M; Plönes T; Forsting M; Wetter A; Herrmann K; Hautzel H; Darwiche K; Theegarten D; Aigner C; Schuler M; Stuschke M; Eberhardt WE
Immunotherapy; 2022 Aug; 14(12):927-944. PubMed ID: 35822656
[TBL] [Abstract][Full Text] [Related]
8. Impact of the pretreatment prognostic nutritional index on the survival after first-line immunotherapy in non-small-cell lung cancer patients.
Oku Y; Toyokawa G; Wakasu S; Kinoshita F; Takamori S; Watanabe K; Haratake N; Nagano T; Kosai K; Takada K; Fujimoto A; Higashijima K; Shiraishi Y; Tanaka K; Takeoka H; Okamoto M; Yamashita T; Shimokawa M; Shoji F; Yamazaki K; Okamoto T; Seto T; Ueda H; Takeo S; Nakashima N; Okamoto I; Takenaka T; Yoshizumi T
Cancer Med; 2023 Jul; 12(13):14327-14336. PubMed ID: 37211905
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of prognostic nutritional index and its variations in advanced non-small-cell lung cancer patients treated with anlotinib monotherapy.
Chen T; Liang G; Xiang Z; He J; Xu X; Tang M
J Clin Lab Anal; 2022 Apr; 36(4):e24300. PubMed ID: 35179795
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapy.
Araki T; Tateishi K; Komatsu M; Sonehara K; Wasamoto S; Koyama S; Yoshiike F; Hama M; Nishie K; Kondo D; Agatsuma T; Kato A; Takata M; Kanda S; Hanaoka M; Koizumi T
Thorac Cancer; 2022 Jul; 13(14):2031-2040. PubMed ID: 35616056
[TBL] [Abstract][Full Text] [Related]
11. Low pretreatment PNI correlates with worse survival in patients with stage III/IV NSCLC who received chemotherapy.
Shen Y; Li H; Yuan ZQ; Ren MY; Yu SL; Liao YD; Cai JJ; Liu C; Chen BC; Wu AH; Li GF; Xie L
Neoplasma; 2020 Mar; 67(2):394-401. PubMed ID: 31847525
[TBL] [Abstract][Full Text] [Related]
12. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study.
Desilets A; Blanc-Durand F; Lau S; Hakozaki T; Kitadai R; Malo J; Belkaid W; Richard C; Messaoudene M; Cvetkovic L; Kazandjian S; Tehfe M; Florescu M; Jao K; Daaboul N; Owen S; Shieh B; Agulnik J; Cohen V; Charbonneau C; Marcoux N; Blais N; Leighl NB; Bradbury PA; Liu G; Shepherd FA; Bahig H; Routy B; Sacher A; Elkrief A
Eur J Cancer; 2021 Jan; 142():83-91. PubMed ID: 33242835
[TBL] [Abstract][Full Text] [Related]
13. Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab.
Jazieh K; Khorrami M; Saad A; Gad M; Gupta A; Patil P; Viswanathan VS; Rajiah P; Nock CJ; Gilkey M; Fu P; Pennell NA; Madabhushi A
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35256515
[TBL] [Abstract][Full Text] [Related]
14. Predictive impact for postoperative recurrence using the preoperative prognostic nutritional index in pathological stage I non-small cell lung cancer.
Shoji F; Morodomi Y; Akamine T; Takamori S; Katsura M; Takada K; Suzuki Y; Fujishita T; Okamoto T; Maehara Y
Lung Cancer; 2016 Aug; 98():15-21. PubMed ID: 27393501
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of decrease in prognostic nutritional index in stage III non-small cell lung cancer patients during curative thoracic radiotherapy.
Kaymak ZA; Ozkan EE
Indian J Cancer; 2021 Jun; ():. PubMed ID: 34380831
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel.
Nishihara-Kato F; Imai H; Tsuda T; Wasamoto S; Nagai Y; Kishikawa T; Miura Y; Ono A; Yamada Y; Masubuchi K; Osaki T; Nakagawa J; Umeda Y; Minemura H; Kozu Y; Taniguchi H; Ohta H; Kaira K; Kagamu H
Oncology; 2024; 102(1):30-42. PubMed ID: 37598676
[TBL] [Abstract][Full Text] [Related]
17. Role of prognostic nutritional index in postoperative radiotherapy for non-small cell lung cancer.
Ryu H; Song C; Kim JS; Jeon JH; Cho S; Kim K; Jheon S; Kim SH; Kim YJ; Lee JS
Thorac Cancer; 2023 Oct; 14(28):2859-2868. PubMed ID: 37594010
[TBL] [Abstract][Full Text] [Related]
18. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
[TBL] [Abstract][Full Text] [Related]
19. Postoperative prognostic nutritional index as a prognostic factor after non-small cell lung cancer surgery.
Hayasaka K; Shiono S; Suzuki K; Endoh M; Okada Y
Gen Thorac Cardiovasc Surg; 2020 Oct; 68(10):1163-1171. PubMed ID: 32328993
[TBL] [Abstract][Full Text] [Related]
20. [Clinical application value of prognostic nutritional index for predicting survival in patients with advanced non-small cell lung cancer].
Xu WJ; Kang YM; Zhou L; Chen FF; Song YH; Zhang CQ
Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):146-149. PubMed ID: 28219213
[No Abstract] [Full Text] [Related]
[Next] [New Search]
